Trial ID or NCT#

NCT01327521

Status

not recruiting iconNOT RECRUITING

Purpose

Primary Objective: To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE. Secondary Objectives: 1. To determine the progression-free survival of TACE vs. CyberKnife SBRT 2. To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC 3. To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of recurrent HCC.

Official Title

International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Samuel So, MD
Samuel So, MD
Surgical oncologist, Liver surgeon, General surgeon
Lui Hac Minh Professor in the School of Medicine
George A. Fisher Jr.
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine
Daniel Sze, MD, PhD
Daniel Sze, MD, PhD
Professor of Radiology (Interventional Radiology)
Nishita Kothary, MD
Nishita Kothary, MD
Professor of Radiology (Interventional Radiology)
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Hepatologist, Transplant hepatologist
Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health
Daniel Chang
Daniel Chang
Sue and Bob McCollum Professor
Brendan C. Visser, MD
Brendan C. Visser, MD
Hepatobiliary surgeon, Pancreatic surgeon, Surgical oncologist
Associate Professor of Surgery (General Surgery)

Contact us to find out if this trial is right for you.

CONTACT

Laurie Ann Columbo
(650) 736-0792